Prevention and Therapy for Colon Cancer by Targeting Cancer Stem Cells

Track Code: 
13KU008M
Summary: 

Novel derivatives of marmelin are anticancer agents that induce apoptosis, affect cancer stem cells, and inhibit tumor growth. Marmelin analogs have potential as chemotherapeutic agents.

Overview: 

Marmelin analogs are novel compounds that are five times more potent than its parent compound in inhibiting tumor growth. Data suggests that the novel derivatives of marmelin are potent anticancer agents and have great potential as chemotherapeutic agents. The compounds not only affect dividing cancer cells, but also cancer stem cells.

Applications: 

Chemotherapeutic candidates against cancer.

How it works: 

Data suggests that the novel compound marmelin is a potent anticancer agent that induces apoptosis during G(1) or G2/M phase of the cell cycle and could be a potential chemotherapeutic candidate. Derivatives of marmelin are potent anticancer agents that induce apoptosis, and affect cancer stem cells to inhibit tumor growth. The lead compound showed IC50 value of as low as 300 nM. The analogs have great potential as chemotherapeutic agents.

Benefits: 

Marmelin analogs are novel compounds that are five times more potent than its parent compound in inhibiting tumor growth. The cyclodextrin derivatives are also water soluble, which makes the compound easier for formulations. More importantly, the compounds not only affect dividing cancer cells, but also cancer stem cells.

Why it is better: 

Current approved chemotherapeutic agents only target fast diving cancer cells and have no effect on stem cells. Marmelin analogs not only target the fast dividing cells, but are equally effective against cancer stem cells.

Other Applications: 

Compounds might have efficacy against colonic inflammation.

Licensing Associate: 
Aswini Betha, PhD · abetha@ku.edu · 913-588-5713
Category(s): 
Subcategory(s): 
Keyword(s): 
Inventor(s): 
Shrikant Anant
Dharmalingam Subramaniam
Subhash Padhye
Patent(s): 
patent_pending